Pre-admission Hyperglycemia and Its Effect on Morbidity and Mortality

Completed

• Conditions: Hyperglycemia

• Registration Number: NCT00871832
• Lead Sponsor: Northwell Health

Brief Summary

It is currently standard of care in many Medical and Surgical ICU's to institute a nurse driven insulin protocol in maintaining tight glucose control in the critical patient. Many articles have been written to address this topic. However, there is no current data regarding the use of glycohemoglobin as a marker of risk of morbidity and mortality. In our study we would like to determine whether or not the HbA1C could be used as a marker of morbidity and mortality. The HbA1C is a simple blood test that may be added on to any CBC collection tube; a blood sample that critical patients have drawn up to several times a day. The investigators would analyze this information in respect to the rest of the clinical data collected regarding the patient's illness.

Detailed Description

Not available

Study Timeline

• Study Start: 2007-05
• Study First Submitted: 2009-03-26
• Study First Submitted QC: 2009-03-27
• Study First Posted: 2009-03-30
• Primary Completion: 2010-03
• Study Completion: 2010-03
• Status Verified: 2013-06
• Last Update Submitted: 2013-06-05
• Last Update Posted: 2013-06-06

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

• All patients admitted to the medical and surgical ICU, and CCU that are 18 year's or older and speak English that give consent.

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
morbidity and mortality	at time of review	looking to see if HbA1C correlates with morbidity (i.e. sepsis, renal failure, length of stay) or death

Trial Locations

Locations (1)

Staten Island University Hospital; 🇺🇸 Staten Island, New York, United States